NBPF3

Summary

NBPF3 (NBPF member 3, HGNC:25076) is a protein-coding gene on chromosome 1p36.12, encoding NBPF family member NBPF3 (Q9H094).

This gene is a member of the neuroblastoma breakpoint family (NBPF) which consists of dozens of recently duplicated genes primarily located in segmental duplications on human chromosome 1. This gene family has experienced its greatest expansion within the human lineage and has expanded, to a lesser extent, among primates in general. Members of this gene family are characterized by tandemly repeated copies of DUF1220 protein domains. DUF1220 copy number variations in human chromosomal region 1q21.1, where most DUF1220 domains are located, have been implicated in a number of developmental and neurogenetic diseases such as microcephaly, macrocephaly, autism, schizophrenia, cognitive disability, congenital heart disease, neuroblastoma, and congenital kidney and urinary tract anomalies. Altered expression of some gene family members is associated with several types of cancer. This gene family contains numerous pseudogenes.

Source: NCBI Gene 84224 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 123 total
• MANE Select transcript: NM_032264

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25076
Approved symbol	NBPF3
Name	NBPF member 3
Location	1p36.12
Locus type	gene with protein product
Status	Approved
Aliases	AE2
Ensembl gene	ENSG00000142794
Ensembl biotype	protein_coding
OMIM	612992
Entrez	84224

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 8 protein_coding, 5 protein_coding_CDS_not_defined, 4 nonsense_mediated_decay

ENST00000318220, ENST00000318249, ENST00000342104, ENST00000434838, ENST00000454000, ENST00000467103, ENST00000469876, ENST00000475869, ENST00000477050, ENST00000478653, ENST00000485941, ENST00000486229, ENST00000619554, ENST00000912011, ENST00000912012, ENST00000912013, ENST00000944218

RefSeq mRNA: 10 — MANE Select: NM_032264 NM_001256416, NM_001256417, NM_001330381, NM_001377491, NM_001377492, NM_001377493, NM_001377494, NM_001377495, NM_001377496, NM_032264

CCDS: CCDS216, CCDS57976, CCDS57977, CCDS81275

Canonical transcript exons

ENST00000318249 — 15 exons

Exon	Start	End
ENSE00001421807	21440137	21440348
ENSE00001814163	21483143	21484900
ENSE00003487448	21468688	21468897
ENSE00003497364	21479349	21479400
ENSE00003524606	21480930	21480981
ENSE00003531648	21482484	21482535
ENSE00003569827	21474900	21474951
ENSE00003594154	21480051	21480223
ENSE00003642335	21444948	21445219
ENSE00003655848	21481597	21481769
ENSE00003723776	21471569	21471783
ENSE00003733610	21478144	21478307
ENSE00003734729	21470632	21470734
ENSE00003747501	21473380	21473585
ENSE00003753961	21472843	21472915

Expression profiles

Bgee: expression breadth ubiquitous, 159 present calls, max score 88.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.2322 / max 143.0471, expressed in 1539 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
1158	2.5231	1364
1159	1.4608	889
1160	0.2224	90
1161	0.0259	4

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	88.20	gold quality
colonic epithelium	UBERON:0000397	84.83	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.08	gold quality
right testis	UBERON:0004534	82.80	gold quality
right adrenal gland cortex	UBERON:0035827	82.76	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.97	gold quality
left testis	UBERON:0004533	81.97	gold quality
sural nerve	UBERON:0015488	81.83	gold quality
right adrenal gland	UBERON:0001233	81.36	gold quality
left adrenal gland cortex	UBERON:0035825	80.67	gold quality
left adrenal gland	UBERON:0001234	80.64	gold quality
ventricular zone	UBERON:0003053	80.60	gold quality
islet of Langerhans	UBERON:0000006	80.57	gold quality
adrenal tissue	UBERON:0018303	80.25	gold quality
testis	UBERON:0000473	79.93	gold quality
right hemisphere of cerebellum	UBERON:0014890	79.86	gold quality
cerebellar hemisphere	UBERON:0002245	79.69	gold quality
cerebellar cortex	UBERON:0002129	79.60	gold quality
ganglionic eminence	UBERON:0004023	79.08	gold quality
adrenal gland	UBERON:0002369	79.04	gold quality
smooth muscle tissue	UBERON:0001135	78.78	gold quality
cortical plate	UBERON:0005343	78.76	gold quality
right lobe of thyroid gland	UBERON:0001119	78.33	gold quality
adrenal cortex	UBERON:0001235	78.28	gold quality
body of stomach	UBERON:0001161	78.26	gold quality
endocervix	UBERON:0000458	78.18	gold quality
rectum	UBERON:0001052	78.15	gold quality
mucosa of stomach	UBERON:0001199	77.82	gold quality
calcaneal tendon	UBERON:0003701	77.70	gold quality
left lobe of thyroid gland	UBERON:0001120	77.66	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.32

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

66 targeting NBPF3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-142-3P	99.62	71.30	974
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-549A-3P	99.54	68.17	825
HSA-MIR-1207-5P	99.49	69.11	2983

Literature-anchored findings (GeneRIF, showing 2)

• Study shows that an NBPF gene lacking this insertion, NBPF3, is expressed in a variety of tissues; thus the effect of HERV(K) LTR insertion on NBPF gene expression remains unknown. (PMID:17391723)
• failed to find a significant association between nbpf3 and schizophrenia. (PMID:29688875)

Cross-species orthologs

0 orthologs

Paralogs (14): NBPF20 (ENSG00000162825), NBPF6 (ENSG00000186086), NBPF4 (ENSG00000196427), NBPF1 (ENSG00000219481), NBPF11 (ENSG00000263956), NBPF15 (ENSG00000266338), NBPF12 (ENSG00000268043), NBPF9 (ENSG00000269713), NBPF8 (ENSG00000270231), NBPF14 (ENSG00000270629), (ENSG00000271254), NBPF19 (ENSG00000271383), NBPF10 (ENSG00000271425), NBPF26 (ENSG00000273136)

Protein

Protein identifiers

NBPF family member NBPF3 — Q9H094 (reviewed: Q9H094)

Alternative names: Neuroblastoma breakpoint family member 3, Protein AE2, Protein SHIIIa4

All UniProt accessions (4): Q9H094, A0A087WUB7, A0A087WUY9, X6RCV0

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in testis and fetal heart, as well as in non small cell lung carcinoma and neuroblastoma cell line.

Miscellaneous. Encoded by one of the numerous copies of NBPF genes clustered in the p36, p12 and q21 region of the chromosome 1.

Similarity. Belongs to the NBPF family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9H094-1	1	yes
Q9H094-2	2
Q9H094-3	3
Q9H094-4	4
Q9H094-5	5

RefSeq proteins (10): NP_001243345, NP_001243346, NP_001317310, NP_001364420, NP_001364421, NP_001364422, NP_001364423, NP_001364424, NP_001364425, NP_115640* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010630	Olduvai_dom	Domain
IPR055306	NBPF	Family

Pfam: PF06758

UniProt features (27 total): sequence conflict 6, domain 5, splice variant 5, sequence variant 4, region of interest 3, compositionally biased region 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H094-F1	47.16	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 44 (showing top): MODULE_480, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, MODULE_427, MODULE_192, chr1p36, LU_EZH2_TARGETS_DN, RBM34_TARGET_GENES, ZFP91_TARGET_GENES, ZSCAN21_TARGET_GENES, MIR3529_3P, MIR4251, MIR1207_5P, MIR4763_3P, MIR4692, MIR4514

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

574 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NBPF3	ALPL	P05186	886
NBPF3	ZNF490	Q9ULM2	565
NBPF3	TBC1D7	Q9P0N9	447
NBPF3	MSH3	P20585	404
NBPF3	ZNF232	Q9UNY5	375
NBPF3	NBDY	A0A0U1RRE5	369
NBPF3	ZNF438	Q7Z4V0	367
NBPF3	ZNG1A	Q9BRT8	364
NBPF3	ZNF593	O00488	352
NBPF3	RHBDD2	Q6NTF9	332
NBPF3	SERHL2	Q9H4I8	330
NBPF3	PMFBP1	Q8TBY8	313
NBPF3	ZNF174	Q15697	305
NBPF3	SLX4IP	Q5VYV7	305
NBPF3	RRP7A	Q9Y3A4	299

IntAct

4 interactions, top by confidence:

A	B	Type	Score
NBPF3	NBPF1	psi-mi:“MI:0915”(physical association)	0.400
NBPF3	TSEN15	psi-mi:“MI:0915”(physical association)	0.370
EWSR1	NBPF3	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (9): NBPF3 (Two-hybrid), NBPF1 (Affinity Capture-MS), TSEN15 (Two-hybrid), NBPF3 (Two-hybrid), NBPF1 (Affinity Capture-MS), NBPF3 (Affinity Capture-RNA), NBPF1 (Affinity Capture-MS), NBPF3 (Affinity Capture-MS), APP (Reconstituted Complex)

ESM2 similar proteins: A0A0J9YY54, A0A494C086, A0A494C0Z2, A0A494C191, A6NHP3, A6NIY4, A6NJR5, A6NNV3, B4DH59, F6SZT2, P0C6Y7, P0CI01, P0DKJ7, P0DKJ8, P0DTA3, P0DUD1, P0DUD2, P0DUD3, P0DUD4, P0DUX0, P0DUX1, P0DV79, P79386, Q08AG5, Q13342, Q16666, Q3BBV2, Q495Y8, Q587J8, Q5JRC9, Q5QGU6, Q5RD14, Q5RKG3, Q63HK3, Q6ITT4, Q7TQI8, Q86T75, Q8IWY8, Q8N660, Q8NFV5

Diamond homologs: A0A087WUL8, B4DH59, P0C2Y1, P0DPF2, P0DPF3, Q32LC2, Q3BBV0, Q3BBV2, Q5TAG4, Q5TI25, Q5VU43, Q5VWK0, Q6P3W6, Q86T75, Q86XG9, Q8N660, Q96M43, Q9H094, A0A096LNW5, A2RUV0, G3I6Z6, O35516, P0DPK3, P0DPK4, P10040, P21783, P46530, P46531, Q01705, Q04721, Q04756, Q07008, Q20911, Q7Z3S9, Q80YT7, Q99466, Q9QW30, Q9UM47, Q19UN5, Q8K389

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

123 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	88
Likely benign	8
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2336 predictions. Top by Δscore:

Variant	Effect	Δscore
1:21440344:CTCAG:C	donor_loss	1.0000
1:21440347:AGGTG:A	donor_loss	1.0000
1:21440348:GGTG:G	donor_loss	1.0000
1:21466155:GG:G	donor_gain	1.0000
1:21466156:GG:G	donor_gain	1.0000
1:21468685:CA:C	acceptor_loss	1.0000
1:21468686:A:AG	acceptor_gain	1.0000
1:21468687:G:GA	acceptor_gain	1.0000
1:21468687:GT:G	acceptor_gain	1.0000
1:21468687:GTC:G	acceptor_gain	1.0000
1:21468687:GTCC:G	acceptor_gain	1.0000
1:21468687:GTCCC:G	acceptor_gain	1.0000
1:21468893:TTACG:T	donor_gain	1.0000
1:21468894:TACG:T	donor_gain	1.0000
1:21468894:TACGG:T	donor_loss	1.0000
1:21468896:CG:C	donor_gain	1.0000
1:21468897:GG:G	donor_gain	1.0000
1:21468897:GGT:G	donor_loss	1.0000
1:21468898:G:GG	donor_gain	1.0000
1:21468898:GT:G	donor_loss	1.0000
1:21468899:T:A	donor_loss	1.0000
1:21470627:CTCA:C	acceptor_loss	1.0000
1:21470628:TCAGA:T	acceptor_loss	1.0000
1:21470629:CAG:C	acceptor_loss	1.0000
1:21470630:A:AG	acceptor_gain	1.0000
1:21470631:G:GG	acceptor_gain	1.0000
1:21470631:GA:G	acceptor_gain	1.0000
1:21470631:GAC:G	acceptor_gain	1.0000
1:21470631:GACT:G	acceptor_gain	1.0000
1:21470733:AGGT:A	donor_loss	1.0000

AlphaMissense

4168 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:21471670:T:C	L183P	0.910
1:21471607:T:C	L162P	0.905
1:21471763:T:C	L214P	0.894
1:21471658:T:C	L179S	0.890
1:21483321:T:C	F613L	0.881
1:21483323:T:A	F613L	0.881
1:21483323:T:G	F613L	0.881
1:21483357:T:C	F625L	0.879
1:21483359:C:A	F625L	0.879
1:21483359:C:G	F625L	0.879
1:21483375:T:C	F631L	0.861
1:21483377:C:A	F631L	0.861
1:21483377:C:G	F631L	0.861
1:21471753:G:C	A211P	0.859
1:21445114:T:C	F10L	0.854
1:21445116:C:A	F10L	0.854
1:21445116:C:G	F10L	0.854
1:21468725:G:A	M57I	0.854
1:21468725:G:C	M57I	0.854
1:21468725:G:T	M57I	0.854
1:21471741:G:A	G207R	0.847
1:21471741:G:C	G207R	0.847
1:21468825:T:C	F91L	0.845
1:21468827:C:A	F91L	0.845
1:21468827:C:G	F91L	0.845
1:21471775:T:C	L218P	0.838
1:21471586:T:A	V155D	0.835
1:21471751:T:C	L210P	0.834
1:21471645:G:C	A175P	0.822
1:21471636:G:T	G172W	0.820

dbSNP variants (sampled 300 via entrez): RS1000086872 (1:21468210 G>A), RS1000360648 (1:21480079 G>A), RS1000367836 (1:21459515 A>G), RS1000375296 (1:21481091 C>G), RS1000642574 (1:21473732 C>G,T), RS1000672243 (1:21479518 T>C), RS1000711571 (1:21447237 A>G), RS1000781960 (1:21453954 CAG>C), RS1000961790 (1:21461211 T>C), RS1001013043 (1:21469674 A>G,T), RS1001059592 (1:21447475 T>C), RS1001086985 (1:21469319 T>G), RS1001168703 (1:21438003 A>G), RS1001260 (1:21467151 G>A), RS1001261 (1:21467242 C>G)

Disease associations

OMIM: gene MIM:612992 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): hereditary breast ovarian cancer syndrome (MONDO:0003582)

Orphanet (1): Hereditary breast and/or ovarian cancer syndrome (Orphanet:145)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST000248_1	Liver enzyme levels	7.000000e-15
GCST000483_4	Folate pathway vitamin levels	4.000000e-11
GCST000703_1	Phosphorus levels	1.000000e-27
GCST001276_11	Liver enzyme levels (alkaline phosphatase)	2.000000e-50
GCST002559_1	Vitamin B levels in ischemic stroke	2.000000e-07
GCST005981_7	Phosphorus levels	7.000000e-18
GCST007260_1	B6 vitamer levels (multivariate analysis)	8.000000e-10
GCST007261_1	Cerebrospinal fluid pyridoxal phosphate levels	2.000000e-07
GCST007262_1	Plasma pyridoxal phosphate levels	6.000000e-06
GCST007263_1	Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio	4.000000e-09
GCST007264_1	Plasma pyridoxal phosphate to pyridoxal ratio	4.000000e-09
GCST007265_1	Plasma pyridoxic acid to pyridoxal phosphate ratio	3.000000e-06
GCST009167_1	Vitamin levels	7.000000e-09
GCST009652_38	Serum alkaline phosphatase levels	2.000000e-118
GCST010396_201	Gut microbiota (bacterial taxa, hurdle binary method)	4.000000e-06
GCST012020_64	Serum metabolite levels	3.000000e-13
GCST90013406_1	Liver enzyme levels (alkaline phosphatase)	1.000000e-300

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004533	alkaline phosphatase measurement
EFO:0004621	vitamin B6 measurement
EFO:0004861	phosphorus measurement
EFO:0004729	vitamin measurement
EFO:0007874	gut microbiome measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D061325	Hereditary Breast and Ovarian Cancer Syndrome	C04.588.180.483; C04.588.322.455.431; C04.700.517; C12.050.351.500.056.630.705.431; C12.050.351.937.418.685.431; C12.100.250.056.630.705.431; C12.900.418.685.431; C16.320.700.517; C17.800.090.500.483; C19.344.410.431; C19.391.630.705.431

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases expression, increases methylation	3
sodium arsenite	decreases expression	2
Benzo(a)pyrene	increases mutagenesis, decreases methylation	2
Tobacco Smoke Pollution	decreases expression	2
bisphenol F	affects cotreatment, decreases expression	1
bufotalin	decreases expression	1
triphenyl phosphate	affects expression	1
2-butenal	decreases expression	1
beta-lapachone	increases expression	1
K 7174	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Amiodarone	increases expression	1
Atrazine	decreases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Copper	affects binding, increases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Disulfiram	affects binding, increases expression	1
Estradiol	affects expression	1
Hydrogen Peroxide	increases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Methylcholanthrene	affects binding, increases reaction	1
Ozone	increases abundance, affects expression	1
1-Methyl-3-isobutylxanthine	decreases expression, affects cotreatment	1
Okadaic Acid	increases expression	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

51 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02562170	PHASE4	COMPLETED	Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study
NCT00673335	PHASE3	COMPLETED	Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
NCT00685256	PHASE3	COMPLETED	Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
NCT03162276	PHASE3	UNKNOWN	Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
NCT00253539	PHASE2	COMPLETED	Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
NCT00305695	PHASE2	COMPLETED	Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
NCT00321633	PHASE2	COMPLETED	Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
NCT01333748	PHASE2	COMPLETED	Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
NCT01367639	PHASE2	COMPLETED	Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
NCT00535119	PHASE1	COMPLETED	Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
NCT00892736	PHASE1	COMPLETED	Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
NCT03832985	EARLY_PHASE1	COMPLETED	Pediatric Reporting of Adult-Onset Genomic Results
NCT00005095	Not specified	RECRUITING	Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT00609505	Not specified	COMPLETED	Telemedicine vs. Face-to-Face Cancer Genetic Counseling
NCT01273909	Not specified	UNKNOWN	Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment
NCT01445275	Not specified	WITHDRAWN	Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
NCT01608074	Not specified	ACTIVE_NOT_RECRUITING	Radical Fimbriectomy for Young BRCA Mutation Carriers
NCT02087592	Not specified	COMPLETED	Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers
NCT02302742	Not specified	RECRUITING	Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
NCT02324062	Not specified	COMPLETED	Cancer Genetics Hereditary Cancer Panel Testing
NCT02516540	Not specified	UNKNOWN	Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers
NCT02653105	Not specified	ACTIVE_NOT_RECRUITING	Women at Risk of Breast Cancer and OLFM4
NCT02705924	Not specified	TERMINATED	Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk
NCT02760849	Not specified	ACTIVE_NOT_RECRUITING	Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
NCT02786147	Not specified	COMPLETED	Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer
NCT02956681	Not specified	COMPLETED	Statewide Communication to Reach Diverse Low Income Women
NCT03015376	Not specified	UNKNOWN	Inherited Susceptible Genes Among Epithelial Ovarian Cancer
NCT03050268	Not specified	RECRUITING	Familial Investigations of Childhood Cancer Predisposition
NCT03075540	Not specified	COMPLETED	Enhancing At-risk Latina Women’s Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer
NCT03124212	Not specified	RECRUITING	Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
NCT03246841	Not specified	ACTIVE_NOT_RECRUITING	Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.
NCT03294343	Not specified	UNKNOWN	Risk-Reducing Surgeries for Hereditary Ovarian Cancer
NCT03421327	Not specified	COMPLETED	Genetic Risk: Whether, When, and How to Tell Adolescents
NCT03510689	Not specified	COMPLETED	Genetics and Heart Health After Cancer Therapy
NCT03511690	Not specified	COMPLETED	Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment
NCT03784859	Not specified	COMPLETED	Tissue Expansion in Breast Reconstruction Without Drains
NCT03979612	Not specified	UNKNOWN	Evaluation of the Adhesion to the GENEPY Network
NCT04197856	Not specified	ACTIVE_NOT_RECRUITING	Direct Information to At-risk Relatives
NCT04407611	Not specified	COMPLETED	Scalable Communication Modalities for Returning Genetic Research Results
NCT04508764	Not specified	TERMINATED	Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome